PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Market Capitalization on January 14, 2025: USD 2.40 M

PainReform Ltd. Market Capitalization is USD 2.40 M on January 14, 2025, a 550,378.38% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

PainReform Ltd. 52-week high Market Capitalization is USD 25.68 M on December 26, 2024, which is 971.47% above the current Market Capitalization.
PainReform Ltd. 52-week low Market Capitalization is USD 78.25 on August 08, 2024, which is -100.00% below the current Market Capitalization.
PainReform Ltd. average Market Capitalization for the last 52 weeks is USD 418.92 K.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years